Copyright
©The Author(s) 2025.
World J Diabetes. Mar 15, 2025; 16(3): 92003
Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.92003
Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.92003
Figure 8 LEF1, as the binding protein of lnc-MGC, regulates the progression of diabetic retinopathy.
A and B: LEF1 can bind to the lnc-MGC promoter; C: Western blotting was used to detect the inhibition efficiency of LEF1; D: RT-qPCR was used to detect the transfection efficiency; E: CCK-8 was used to measure the cell proliferation activity; F: TUNEL was used to detect cell apoptosis. The scale bar represents 100 μm; G: ELISA was used to determine the expression of the inflammatory cytokines TNF-α, IL-1β and IL-6; H: Flow cytometry was used to detect reactive oxygen species; I-K: Western blotting was used to detect the expression of related proteins. aP < 0.05, bP < 0.01, and cP < 0.001. NC: Normal control; HG: High glucose; ROS: Reactive oxygen species.
- Citation: Luo YY, Ba XY, Wang L, Zhang YP, Xu H, Chen PQ, Zhang LB, Han J, Luo H. LEF1 influences diabetic retinopathy and retinal pigment epithelial cell ferroptosis via the miR-495-3p/GRP78 axis through lnc-MGC. World J Diabetes 2025; 16(3): 92003
- URL: https://www.wjgnet.com/1948-9358/full/v16/i3/92003.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i3.92003